Personalized dasatinib dosing aims to tame leukemia with fewer side effects
NCT ID NCT01916785
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether adjusting the daily dose of the leukemia drug dasatinib based on a patient's blood levels can improve safety and effectiveness. Adults newly diagnosed with chronic phase chronic myeloid leukemia (CML) will receive either standard dosing or a dose tailored to their dasatinib blood levels. The goal is to reduce serious side effects while maintaining control of the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dasatinib (Sprycel)
- What this could lead to
- If successful, this approach could reduce side effects and improve treatment outcomes for people with chronic myeloid leukemia by personalizing their daily dose.
- What could go wrong
- This is a Phase 2 trial, so the strategy may not prove better than standard dosing. There is also a risk of side effects like fluid retention or low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA, BCR/ABL POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
C.H.U. Brabois
Nancy, France
-
CH Lyon Sud
Lyon, France
-
CH Pierre LeGardeur
Lachenaie, Canada
-
CH René Dubos
Cergy-Pontoise, France
-
CHRU Bretonneau
Tours, France
-
CHU Angers
Angers, France
-
CHU Caremeau
Nîmes, France
-
CHU Hoptel dieu
Nantes, France
-
CHU Poitiers
Poitiers, France
-
CHU Rennes - Pontchaillou
Rennes, France
-
Central Hospital
Versailles, France
-
Centre René Huguenin
Saint-Cloud, France
-
Hopital Henri MONDOR
Créteil, France
-
Hopital MORVAN
Brest, France
-
Hopital Saint Louis
Paris, France
-
Hôpital Avicenne
Bobigny, France
-
Hôpital Charles LeMoyne
Greenfield Park, Canada
-
Hôpital Claude Huriez
Lille, France
-
Hôpital Général Juif - Sir. Mortimer B. Davis
Montreal, Canada
-
Hôpital Maisonneuve-Rosemont
Montreal, Canada
-
Hôpital Necker-Enfants Malades
Paris, France
-
Hôpital Purpan
Toulouse, France
-
Hôpital Royal Victoria
Montreal, Canada
-
Hôpital St Antoine
Paris, France
-
Hôpital d'Annecy
Metz-Tessy, France
-
Hôpital d'Instruction de Armées Percy
Clamart, France
-
Hôpital de l'Enfant Jésus - Centre hospitalier affilié universitaire de Québec
Québec, Canada
-
Hôpital l'Archet 1
Nice, France
-
Institut Bergonie
Bordeaux, France
-
Institut Paoli-Calmettes
Marseille, France
-
Moncton City Hospital
Moncton, Canada
-
Pavillon Hôtel-Dieu de Québec - Centre hospitalier universitaire de Québec
Québec, Canada
-
Queen elisabeth II Health Sciences Center
Halifax, Canada
-
Southern Alberta Cancer Research Institute
Calgary, Canada